Oct 23, 2018
Ocugen to Highlight Phase 2 Clinical Data for OCU310 at AAO 2018
Oct 01, 2018
Ocugen Initiates Phase 3 Clinical Trial of OCU310 for Dry Eye Disease
Sep 26, 2018
Ocugen to Present at Two Upcoming Investor Conferences
Aug 13, 2018
Ocugen Appoints James G. Murphy, CPA, as Chief Financial Officer
May 29, 2018
Ocugen to Present at the 2018 BIO International Convention
May 02, 2018
Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018
Apr 25, 2018
Ocugen to Highlight Potential Efficacy of its Proprietary Nanoemulsion Technology at ARVO 2018
Apr 23, 2018
Ocugen Announces CEO Dr. Shankar Musunuri Named a Finalist for Ernst & Young Entrepreneur Of The Year® 2018 Award
Mar 20, 2018
Ocugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel Combination Therapy for Dry Eye Disease
Mar 15, 2018
Ocugen to Present at the Oppenheimer 28th Annual Healthcare Conference
Feb 06, 2018
Ocugen to Present at 2018 BIO CEO & Investor Conference
Dec 20, 2017
Ocugen Expands Focus on Inherited Retinal Disorders by Licensing Novel Modifier Gene Therapy Platform
Sep 25, 2017
Ocugen Announces FDA Acceptance of Investigational New Drug Application for OCU310 (brimonidine/steroid combination therapy) and Initiates Proof of Concept Study for Treatment of Dry Eye Disease
Aug 28, 2017
Ocugen Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017
Aug 09, 2017
Ocugen Receives FDA Orphan Drug Designation for OCU300 (brimonidine tartrate) for the Treatment of Ocular Graft Versus Host Disease
Jun 19, 2017
Ocugen Makes Strategic Appointments to Management Team
Jun 15, 2017
Ocugen Closes $7.5 Million Series B Financing